DBV Technologies’ 2013 Financial calendar


- Full-year 2012 top-line Thursday, January 31st 2013
- Full-year 2012 results Monday, March 4th 2013
- First quarter 2013 top-line Monday, April 15th 2013
- Half-year 2013 results Friday, July 26th 2013
- First nine months 2013 top-line Tuesday, October 15th 2013

*This financial calendar is for indicative purposes only and DBV Technologies could change its publication dates should it deem it necessary.

Dr. Pierre-Henri Benhamou, Chairman & CEO of DBV Technologies, said: “Since our IPO in March 2012, which allowed us to raise over 40 million euros and therefore secure our development for the coming years, DBV has endeavoured to strictly comply with all of its strategic objectives. In particular, we initiated our international Phase IIb clinical study on Viaskin® Peanut which benefits from a Fast Track with the FDA, and also kicked off the development of our third product, Viaskin® HDM for House Dust Mites allergy in young children. At the same time, the company has surrounded itself with top-notch experts from the allergy field, notably with the addition of Professor Sampson from Mount Sinai Hospital in New York to DBV’ Scientific Advisory Board. Undoubtedly, DBV today gathers the greatest specialists worldwide in allergy. In parallel, DBV has set up landmark partnerships with leading French and international research organisations. I am very grateful to DBV’s outstanding team for these achievements, and also to our shareholders, whose remarkable support throughout this cornerstone year has been instrumental in progressing at fast pace toward the future commercialisation of medicines that will radically change the lives of millions of allergy sufferers worldwide.”

About DBV Technologies

DBV Technologies is opening up a decisive new approach to the treatment of allergy – a major public health issue that is constantly increasing in prevalence. Food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. DBV Technologies has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. The Viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient’s tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. The company’s significant development program has taken this revolutionary method through to the industrial stage in Europe, initially. The product’s clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. DBV Technologies is focusing on food allergies (milk and peanut) for which there are currently no effective treatments. It has developed two products: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration. The company will subsequently develop a Viaskin® patch for young children with house dust mite allergy – a true public health issue because this pathology is one of the main risk factors for childhood asthma. DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345).

For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

CAUTION: Viaskin® is not approved for sale in the USA.

DBV Contacts

David Schilansky  
Chief Financial Officer  
DBV Technologies  
Tél. : +33(0)1 55 42 78 75  
david.schilansky@dbv-technologies.com

NewCap.  
Emmanuel Huynh / Alexandra Schiltz  
Tél.: +33(0)1 44 71 94 94  
dbv@newcap.fr

Ronald Trahan, APR  
Press relations  
Ronald Trahan  
Tél. : +1 508 359 4005  
rctrahan@ronaldtrahan.com